AstraZeneca is investing $3.5 billion to expand biopharmaceutical research and manufacturing in the US by 2026, with $2 billion focused on creating over 1,000 skilled jobs.
This includes growing its cell therapy manufacturing on the East and West coasts, with plans for California, Maryland, and Texas.